Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 423

1. BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer Thyroid · 2014 · 188 citations
2. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma British Journal of Dermatology · 2012 · 173 citations
3. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. Journal of the European Academy of Dermatology and Venereology · 2014 · 31 citations
4. Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis Acta neuropathologica communications · 2019 · 29 citations
5. B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance Cell Reports · 2012 · 26 citations
6. Network pharmacology and molecular docking analysis on potential molecular targets and mechanism of action of BRAF inhibitors for application in wound healing Journal of Cellular Biochemistry · 2023 · 11 citations
7. The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis Cutaneous and Ocular Toxicology · 2018 · 9 citations
8. The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma Current Dermatology Reports · 2013 · 6 citations
9. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects PLOS ONE · 2021 · 3 citations
10. Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors Journal of The American Academy of Dermatology · 2018 · 1 citations

Community

— no results